Business Context and Reporting Period
Company: The Cooper Companies, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and nine months ended July 31, 1995.
Business Overview: The Company develops, manufactures, and markets healthcare products (contact lenses, surgical instruments) and operates psychiatric facilities. The Company has shifted strategic focus from long-term R&D to acquiring market-ready products.
Key Financial Metrics
| Metric (in thousands) | 9 Months Ended July 31, 1995 | 9 Months Ended July 31, 1994 |
|---|---|---|
| Net Operating Revenue | $72,253 | $71,263 |
| Income from Operations | $5,422 | $(772) |
| Net Income (Applicable to Common) | $3,700 | $(6,000) |
| Diluted EPS | $0.11 | $(0.20) |
| Operating Cash Flow | $(1,651) | $(3,332) |
| Cash and Equivalents (End of Period) | $8,786 | $9,720 |
| Total Debt (Current + Long-term) | $48,792 | $49,442 |
| Stockholders' Equity | $664 | $(3,654) |
Margins: Gross margin for products was 68% for the nine months ended July 31, 1995, compared to 65% in the prior year. Service revenue margin was 4.6% for the nine-month period.
Material Changes vs. Prior Period
- Profitability Turnaround: The Company returned to profitability, reporting $3.7 million in net income for the nine months ended July 31, 1995, compared to a $6.0 million loss in the prior year. Operating income improved by $6.2 million.
- Revenue Growth: Net sales of products increased 7% year-over-year, driven by an 11% increase in CooperVision, Inc. (CVI) sales. Net service revenue decreased 5% due to managed care pressures and a dispute at Hampton Hospital.
- Expense Reduction: Selling, General, and Administrative (SG&A) expenses decreased 16% due to legal matter resolutions and corporate staffing reductions. R&D expenses decreased 22% as the Company discontinued funding for certain high-risk projects.
- Unusual Items: A $1.5 million credit to income was recorded for the settlement of disputes, including insurance recoveries and adjustments to accruals. This contrasts with a $5.0 million charge for dispute settlements in the prior year.
Outlook, Risks, and Contingencies
- Liquidity and Capital: Management believes the Company can fund internal operating needs. A $8 million credit facility exists, with $2.9 million drawn as of July 31, 1995. The Company is exploring methods to raise additional capital for acquisitions.
- Legal Proceedings:
- Hampton Medical Group (HMG): Ongoing arbitration and litigation regarding billing fraud and contract termination. A settlement is being negotiated which could require payments to HMG, potentially impacting fiscal 1995 net income. Management expects long-term financial condition to improve post-termination.
- Shareholder Derivative Actions: Two derivative lawsuits allege securities fraud and fiduciary duty violations. Settlements are being negotiated with no expected material impact on the Company.
- Subsequent Event: On August 30, 1995, the Company's stock price triggered the final payout of the Turnaround Incentive Plan (TIP), totaling approximately $476,000 in cash and 292,000 restricted shares.
Investor Verification Checklist
- Verify the status and potential financial impact of the settlement negotiations with Hampton Medical Group (HMG).
- Confirm the sustainability of the 11% revenue growth in the CooperVision (CVI) segment.
- Monitor the utilization of the $8 million credit facility and any new capital raising activities.
- Review the final terms of the shareholder derivative litigation settlements.
- Assess the impact of the Turnaround Incentive Plan (TIP) payout on cash flow in the subsequent quarter.